Annual report pursuant to Section 13 and 15(d)

Subsequent Events - Additional Information (Detail)

v3.7.0.1
Subsequent Events - Additional Information (Detail)
12 Months Ended
Feb. 27, 2017
USD ($)
Jan. 04, 2017
EUR (€)
Jan. 04, 2017
USD ($)
Dec. 31, 2016
USD ($)
Jan. 04, 2017
USD ($)
Subsequent Event [Line Items]          
Collaboration agreement, license upfront payment       $ 2,735,794  
Subsequent Event [Member] | FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Upfront Payment Arrangement [Member]          
Subsequent Event [Line Items]          
Collaboration agreement, license upfront payment   € 30,000,000 $ 31,300,000    
Subsequent Event [Member] | FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Minimum [Member]          
Subsequent Event [Line Items]          
Contractual agreement, potential payments   € 1,700,000,000     $ 1,800,000,000
Subsequent Event [Member] | Option Agreement [Member] | ASKA Pharmaceutical Co Ltd [Member]          
Subsequent Event [Line Items]          
Option payment receivable $ 2,750,000        
Subsequent Event [Member] | Collaborative Arrangement, Product [Member] | ASKA Pharmaceutical Co Ltd [Member]          
Subsequent Event [Line Items]          
Option exercise fee and milestone payments $ 80,000,000